5 updates on drugs being tested to treat COVID-19

The latest on several drugs being tested for the treatment of COVID-19: 

  1. Eli Lilly's rheumatoid arthritis drug baricitinib, sold under the brand name Olumiant, prevented 1 death for every 6 patients on a ventilator in a phase 3 clinical trial. 

  1. The FDA revised its emergency use authorization for Regeneron's COVID-19 antibody cocktail of casirivimab and imdevimab, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.

  1. Bamlanivimab or casirivimab-imdevimab, two monoclonal antibodies, were effective in preventing hospitalization among high-risk patients with COVID-19 when administered separately in a real-world study.  

  1. Gilead's remdesivir may be associated with longer hospital stays for COVID-19 patients, even after they have recovered, so that they can finish the treatment course, a study suggested.

  1. The antibiotic azithromycin didn't reduce the risk of hospitalization, respiratory failure or death in COVID-19 patients in a clinical trial.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars